
The company will likely see a steady rise in revenue led by continued market share gains for its drugs – Darzalex, Stelara, Erleada, and Tremfya.
The company will likely see a steady rise in revenue led by continued market share gains for its drugs – Darzalex, Stelara, Erleada, and Tremfya.